Pathways leading to TP53 dysregulation represent a common element in non-TP53 mutated AML, hence leveraging WT TP53 in unmutated AML serves as a corner stone in the design of anti-AML therapeutic strategies. This evidence concerns the gene TP53 and acute myeloid leukemia.